Developing siRNA therapies to address osteoporosis

about

Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.Appropriate models for novel osteoporosis drug discovery and future perspectives.Construction of a PLGA based, targeted siRNA delivery system for treatment of osteoporosis.

P2860

Q37325079-D260C0B4-F507-4717-A302-F89E6135AFDA Q38570326-72791665-52F5-4894-9FAB-2597DAAB93FD Q47908177-45A51DE5-9872-42B3-8734-730FFCF4DE80

P2860

Developing siRNA therapies to address osteoporosis

Item

http://www.wikidata.org/entity/Q38151734

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Developing siRNA therapies to address osteoporosis

@en

type

Item

label

Developing siRNA therapies to address osteoporosis

@en

prefLabel

Developing siRNA therapies to address osteoporosis

@en

P1476

Developing siRNA therapies to address osteoporosis

@en

P2093

David W Grainger

http://www.w3.org/2001/XMLSchema#string

Yuwei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Chordin knockdown enhances the osteogenic differentiation of human mesenchymal stem cells

Wnt modulators in the biotech pipeline

The promises and pitfalls of RNA-interference-based therapeutics

Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.

First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

siRNA nanoparticle functionalization of nanostructured scaffolds enables controlled multilineage differentiation of stem cells.

RNAi therapeutics: principles, prospects and challenges.

RNAi-based therapeutics-current status, challenges and prospects

P304

1239-1246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/TDE.13.85

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257749904

http://www.w3.org/2001/XMLSchema#string

P698

24116909

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

P932

3891929

http://www.w3.org/2001/XMLSchema#string

Developing siRNA therapies to address osteoporosis

about

P2860

P2860

Developing siRNA therapies to address osteoporosis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932